ArticleAllergy, asthma & immunology research2021
Severe Cutaneous Adverse Reactions to Anti-tuberculosis Drugs in Korean Patients.
Article in Allergy, asthma & immunology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Rechallenge with First-Line Anti-Tubercular Therapy After Toxic Epidermal Necrolysis in an HIV-Positive Patient with Tubercular Pleural Effusion.Indian dermatology online journal · 2026Article
- An international scoping review of epidemiologic studies on severe cutaneous adverse reactions.The World Allergy Organization journal · 2026Article
- Management of patients with tuberculosis medication-induced drug reaction with eosinophilia and systemic symptoms.Current opinion in allergy and clinical immunology · 2025Review
- Severe cutaneous adverse drug reactions due to antituberculosis drugs and their management.Northern clinics of Istanbul · 2025Article
- Overlapping of DRESS and Stevens-Johnson syndrome due to first-line antituberculosis drugs: a case report.Therapeutic advances in drug safety · 2025Article
- Article
- Delayed drug hypersensitivity to anti-tuberculosis drug: a new desensitization scheme.Postepy dermatologii i alergologii · 2024Article
- DRESS syndrome due to anti-TB drugs: A complex case with successful re-desensitization of group A drugs.Journal of family medicine and primary care · 2024Article
- Antituberculosis-Drugs Induced DRESS: A Multidrug Hypersensitivity or Drug Hypersensitivity Relapse? A Case Report.Hospital pharmacy · 2024Article
- Hypersensitivity reactions with first-line antituberculosis drugs and outcomes of rapid desensitizations.The World Allergy Organization journal · 2024Article
- HIV-associated photodermatitis in African populations.Frontiers in allergy · 2023Review
- Skin infiltrating T-cell profile of drug reaction with eosinophilia and systemic symptoms (DRESS) reactions among HIV-infected patients.Frontiers in medicine · 2023Article
- IFN-γ ELISpot in Severe Cutaneous Adverse Reactions to First-Line Antituberculosis Drugs in an HIV Endemic Setting.The Journal of investigative dermatology · 2022Article
- Analysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System.Journal of Korean medical science · 2022Article
- High occurrence of simultaneous multiple-drug hypersensitivity syndrome induced by first-line anti-tuberculosis drugs.The World Allergy Organization journal · 2021Article
- Severe Cutaneous Adverse Reactions Caused by Anti-Tubercular Drugs.Allergy, asthma & immunology research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 13 institutions in 2 countries.
Funding
Abstract
purposeAnti-tuberculosis drugs (ATDs) can cause severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS). Underlying tuberculous infection and co-administration of multiple drugs may contribute to the complexity of ATD-related SCARs. This study aimed to investigate the clinical characteristics and outcomes of ATD-related SCARs.
methodsWe analyzed ATD-related SCAR cases in 2010-2015, selected from a web-based Database of the Korean Registry of SCAR.
resultsAmong 783, 53 patients with ATD-induced SCARs were enrolled, including 12 with SJS/TEN (22.6%) and 41 with DRESS (77.4%). When comparing the ATD and non-ATD groups, the prevalence of DRESS patients was higher in the ATD group than in the non-ATD group (77.4% vs. 45.8%,
conclusionsDRESS was more common among the ATD-related SCAR cases. Although treatment with most ATDs carries the risk of SCAR development, the use of rifampin was most frequently involved in the occurrence of SCARs. Multiple hypersensitivity was frequently observed in ATD-related SCARs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.